Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Clinical trial NCT01461538 · COMPLETED

Trial details

NCT number: NCT01461538
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoid Leukemia Acute Myeloid Leukemia Anemia, Refractory, With Excess of Blasts Solid Tumors

Start date: 2011-10-01
Primary completion: 2014-12-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.